ImmuneAGE Bio
Private Company
Total funding raised: $2.5M
Overview
ImmuneAGE Bio is an early-stage biotech venture targeting the burgeoning field of immune senescence. The company aims to translate research on how the aging immune system drives chronic disease into therapeutic interventions. Based in the life sciences hub of Basel, Switzerland, it leverages a dual approach of small molecules and advanced therapies. As a private, pre-clinical entity, its success hinges on validating its platform and advancing its first programs into the clinic.
Technology Platform
Proprietary platform targeting pathways of immune aging for drug discovery in small molecules and cell & gene therapies.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competition is intensifying from both well-funded longevity biotech startups (e.g., Unity Biotechnology, Altos Labs, Calico) and large pharmaceutical companies investing in aging research. ImmuneAGE Bio must differentiate through a unique mechanistic approach or superior platform validation in the crowded immunology space.